Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARRY
  • CUSIP: 04269X10
Key Metrics:
  • Previous Close: $10.36
  • 50 Day Moving Average: $10.84
  • 200 Day Moving Average: $7.26
  • 52-Week Range: $2.50 - $13.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.19
  • P/E Growth: -1.49
  • Market Cap: $1.75B
  • Outstanding Shares: 169,007,000
  • Beta: 2.12
Profitability:
  • Net Margins: -58.57%
  • Return on Assets: -49.54%
Debt:
  • Debt-to-Equity Ratio: 2.26%
  • Current Ratio: 4.10%
  • Quick Ratio: 4.10%
Additional Links:
Companies Related to Array BioPharma:

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $11.50 (11.00% upside)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetDetails
2/10/2017Cowen and CompanyReiterated RatingOutperform$10.00 -> $15.00View Rating Details
2/9/2017Cantor FitzgeraldSet Price TargetBuy$13.00View Rating Details
2/3/2017Stifel NicolausBoost Price TargetBuy$8.00 -> $13.00View Rating Details
2/3/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$10.00View Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00View Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetBuy$15.00View Rating Details
11/11/2016Jefferies Group LLCReiterated RatingBuy$8.00View Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Array BioPharma (NASDAQ:ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.18)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
Current Year EPS Consensus Estimate: $-0.73 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.18)($0.15)($0.16)
Q2 20163($0.18)($0.14)($0.16)
Q4 20163($0.27)$0.09($0.13)
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.25)($0.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 88.58%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Array BioPharma (NASDAQ:ARRY)
DateHeadline
schaeffersresearch.com logo2 Biotechs Ready to Rocket - Schaeffers Research (blog) (NASDAQ:ARRY)
www.schaeffersresearch.com - February 23 at 8:39 PM
fool.com logoHow High Can Array BioPharma Inc. Stock Go? - Motley Fool (NASDAQ:ARRY)
www.fool.com - February 23 at 8:39 PM
News IconPrice Index Watch on Shares of Array BioPharma Inc. (NASDAQ:ARRY) - The Standard (NASDAQ:ARRY)
6milestandard.com - February 23 at 3:39 PM
News IconTale of the Tape: Technical Recap for Array Biopharma Inc (ARRY) - Sherwood Daily (NASDAQ:ARRY)
sherwooddaily.com - February 22 at 3:37 PM
News IconSmart Money Buying the Price Weakness of Array BioPharma Inc. (ARRY) - Money Flow Index & Trends (NASDAQ:ARRY)
www.moneyflowtrends.com - February 22 at 3:37 PM
fool.com logoHow High Can Array BioPharma Inc. Stock Go? (NASDAQ:ARRY)
www.fool.com - February 22 at 3:37 PM
News IconAre Insiders Shedding Shares of Array BioPharma Inc. (NASDAQ:ARRY)? - Winfield Review (NASDAQ:ARRY)
winfieldreview.com - February 22 at 11:24 AM
News IconAnalyst's Watch: Array Biopharma Inc (NASDAQ:ARRY) - Post Registrar (NASDAQ:ARRY)
postregistrar.com - February 22 at 11:24 AM
News IconSell-Side Analyst's Predictions: ArQule, Inc. (ARQL), Array BioPharma Inc. (ARRY) - The USA Commerce (NASDAQ:ARRY)
www.theusacommerce.com - February 21 at 3:54 PM
News IconArray BioPharma Inc. (NASDAQ:ARRY) Bearish Target At $15 - Stock Observer (NASDAQ:ARRY)
www.thestockobserver.com - February 21 at 8:59 AM
News IconChecking Indicator Levels for Array BioPharma Inc. (ARRY) - Baldwin Journal (NASDAQ:ARRY)
baldwinjournal.com - February 18 at 9:43 AM
News IconAnalysts Upgrade/Downgrade Activity of Array BioPharma Inc. (NASDAQ:ARRY) (NASDAQ:ARRY)
brassale.net - February 17 at 6:31 PM
News IconArray Biopharma Inc (NASDAQ:ARRY) Updates On 2Q2017 Financial Performance (NASDAQ:ARRY)
giftedviz.com - February 17 at 6:31 PM
News IconArray BioPharma Inc. (NASDAQ:ARRY), Novan, Inc. (NASDAQ:NOVN) (NASDAQ:ARRY)
cloudhostinghq.net - February 17 at 6:31 PM
News IconStock Price of Array BioPharma Inc. (ARRY) Increases 11.43% (NASDAQ:ARRY)
www.graffiotech.com - February 16 at 8:42 PM
News IconPinnacle Associates Ltd. Has $28212000 Position in Array BioPharma Inc. (ARRY) (NASDAQ:ARRY)
techknowbits.com - February 16 at 8:42 PM
News IconAnalysts Estimates and Ratings: Array BioPharma Incorporated (NASDAQ:ARRY) (NASDAQ:ARRY)
mundoaguaysaneamiento.net - February 16 at 8:42 PM
News IconArray Biopharma Inc (NASDAQ:ARRY) Updates On 2Q2017 Financial Performance - FinancialsTrend (NASDAQ:ARRY)
www.financialstrend.com - February 16 at 3:42 PM
News IconChecking Out the Technicals for Array BioPharma Inc. (ARRY) - The USA Commerce (NASDAQ:ARRY)
theusacommerce.com - February 16 at 3:42 PM
News IconAnalysts Near-Term outlook: OneMain Holdings, Inc. (OMF), Array BioPharma Inc. (ARRY) - The USA Commerce (NASDAQ:ARRY)
theusacommerce.com - February 16 at 8:33 AM
News IconTaking a Look at the Data Behind Array BioPharma Inc. (ARRY) - StockNewsJournal (NASDAQ:ARRY)
stocknewsjournal.com - February 16 at 8:33 AM
fool.com logoWant to Get In on Biotech? Check Out These 3 Stocks (NASDAQ:ARRY)
www.fool.com - February 16 at 8:33 AM
News IconToday Analysts Focus on Sunoco Logistics Partners LP (SXL), Array BioPharma Inc. (ARRY) - StockNewsJournal (NASDAQ:ARRY)
stocknewsjournal.com - February 14 at 4:16 PM
News IconArray BioPharma Inc. (ARRY) : Checking the Chart - The USA Commerce (NASDAQ:ARRY)
theusacommerce.com - February 14 at 4:16 PM
finance.yahoo.com logoARRAY BIOPHARMA INC Financials (NASDAQ:ARRY)
finance.yahoo.com - February 14 at 4:16 PM
capitalcube.com logoETFs with exposure to Array BioPharma, Inc. : February 14, 2017 (NASDAQ:ARRY)
www.capitalcube.com - February 14 at 4:16 PM
News IconArray BioPharma Inc. (NASDAQ:ARRY) Bearish Target At $15 ... - Stock Observer (NASDAQ:ARRY)
www.thestockobserver.com - February 13 at 4:06 PM
capitalcube.com logoArray BioPharma, Inc. :ARRY-US: Earnings Analysis: Q2, 2017 By the Numbers : February 13, 2017 (NASDAQ:ARRY)
www.capitalcube.com - February 13 at 4:06 PM
News IconArray BioPharma Inc. (NASDAQ:ARRY) Mean Price Target At ... - Transcript Daily (NASDAQ:ARRY)
transcriptdaily.com - February 12 at 3:39 PM
marketexclusive.com logoAnalyst Activity – Cowen and Company Reiterates Outperform on ... - Market Exclusive (NASDAQ:ARRY)
marketexclusive.com - February 12 at 3:39 PM
News IconArray BioPharma's (ARRY) "Outperform" Rating Reaffirmed at Cowen and Company (NASDAQ:ARRY)
eleganthomesinla.com - February 12 at 1:37 AM
News IconArray BioPharma Inc. (ARRY) Given a $13.00 Price Target at Cantor Fitzgerald (NASDAQ:ARRY)
fairydetox.org - February 12 at 1:37 AM
News IconArray BioPharma Inc. (NASDAQ:ARRY) Analyst Estimates And Rating (NASDAQ:ARRY)
hoyentv.com - February 12 at 1:37 AM
News IconIs It Time to go for Southwestern Energy Company (SWN), Array BioPharma Inc. (ARRY)? - StockNewsJournal (NASDAQ:ARRY)
stocknewsjournal.com - February 11 at 3:36 PM
smarteranalyst.com logoCantor Reiterates Positive Stance on Array Biopharma Inc (ARRY) - Smarter Analyst (NASDAQ:ARRY)
www.smarteranalyst.com - February 11 at 3:36 PM
News IconCantor Reiterates Positive Stance on Array Biopharma Inc (ARRY) (NASDAQ:ARRY)
nyhetsbanken.info - February 11 at 2:09 AM
News IconPulmatrix, Inc. (NASDAQ:PULM), Array BioPharma Inc. (NASDAQ:ARRY) (NASDAQ:ARRY)
eleganthomesinla.com - February 10 at 9:09 PM
News IconArray BioPharma Inc. (ARRY) Announces Earnings Results, Beats Expectations By $0.04 EPS (NASDAQ:ARRY)
xboxonezone.com - February 10 at 9:09 PM
News IconArray BioPharma’s revenue up, loss trimmed during most recent quarter (NASDAQ:ARRY)
bizwest.com - February 10 at 4:08 PM
News IconSphera Funds Management LTD. Invests $6075000 in Array BioPharma Inc. (ARRY) (NASDAQ:ARRY)
xboxonezone.com - February 10 at 4:08 PM
us.rd.yahoo.com logo8:33 am Array Biopharma beats by $0.06, beats on revs (NASDAQ:ARRY)
us.rd.yahoo.com - February 10 at 4:08 PM
biz.yahoo.com logoARRAY BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib (NASDAQ:ARRY)
us.rd.yahoo.com - February 10 at 4:08 PM
us.rd.yahoo.com logoEdited Transcript of ARRY earnings conference call or presentation 9-Feb-17 2:00pm GMT (NASDAQ:ARRY)
us.rd.yahoo.com - February 10 at 4:08 PM
fool.com logoIs Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017? (NASDAQ:ARRY)
www.fool.com - February 10 at 8:55 AM
fool.com logoHere's Why Array Biopharma Inc Stock Is Climbing Again Today (NASDAQ:ARRY)
www.fool.com - February 9 at 8:46 PM
News IconMarket Rover: Looking at Levels on Shares of Array BioPharma Inc. (ARRY) - Benton Bulletin (NASDAQ:ARRY)
bentonbulletin.com - February 9 at 3:43 PM
investopedia.com logoArray BioPharma 2Q Loss Beats Street (ARRY) - Investopedia (NASDAQ:ARRY)
www.investopedia.com - February 9 at 3:43 PM
sg.finance.yahoo.com logoArray BioPharma reports 2Q loss (NASDAQ:ARRY)
sg.finance.yahoo.com - February 9 at 3:43 PM
biz.yahoo.com logoArray Biopharma Inc Earnings Call scheduled for 9:00 am ET today (NASDAQ:ARRY)
biz.yahoo.com - February 9 at 3:43 PM
investopedia.com logoArray BioPharma 4Q Loss 14c/Share Beats Street (NASDAQ:ARRY)
www.investopedia.com - February 9 at 3:43 PM

Social

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

8 brokerages have issued 1-year target prices for Array BioPharma's shares. Their predictions range from $7.00 to $15.00. On average, they expect Array BioPharma's stock price to reach $11.50 in the next year.

When will Array BioPharma announce their earnings?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (1/31/2017)

  • Leerink Swann analysts commented, "We’re at 95% probability-of-success; the current stock valuation prices in less. We believe melanoma represents a small and competitive market, but better tolerability and potential combinability vs. other TKIs could drive differentiation. ARRY also plans to broaden development of encorafenib/ binimetinib in BRAF+ colorectal cancer, which is compelling longer term. Selumetinib Ph III results in KRAS+ Non Small Cell Lung Cancer (NSCLC) are expected in 2H. Updating estimates to reflect F3Q16 results. Maintaining OP rating and $6 PT. Binimetinib regulatory filing in NRAS+ melanoma still expected in 1H16; NEMO full data at ASCO, June 6th. We currently forecast 2025E US sales of $24M with peak penetration of 50% in NRAS+ 2nd/3rd-line melanoma following immune-oncology (IO) therapies, which currently dominate the 1st and 2nd lines of therapy in these pts. Given the poor prognosis of NRAS+ pts, some 2L use is likely. ARRY previously reported a median progression-free survival (PFS) of 2.8 months and plans to report full Ph III data including ORR (Objective Response Rate) and subgroup analysis (PFS & ORR) in IO-treated patients at ASCO. COLUMBUS trial (BRAF+ melanoma) top-line data exp. in 3Q16 (vs. 1H16 prev.) as additional events are needed to trigger the final analysis (which is not uncommon, in our view). We currently assume a 95% probability-of-success (POS) with 20% peak market share (conservative) among MEK/BRAF-treated pts. A potl." (5/5/2016)

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.71%), Orbimed Advisors LLC (9.52%), State Street Corp (3.81%), Franklin Resources Inc. (3.30%), Pinnacle Associates Ltd. (1.90%) and Bogle Investment Management L P DE (1.23%). Company insiders that own Array BioPharma stock include Andrews R Robbins, Kyle Lefkoff, Redmile Group, Llc and Ron Squarer.

Who sold Array BioPharma stock? Who is selling Array BioPharma stock?

Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Pinnacle Associates Ltd. and Kopp Investment Advisors LLC.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Franklin Resources Inc., Bogle Investment Management L P DE, FMR LLC, Guggenheim Capital LLC, AQR Capital Management LLC and Putnam Investments LLC.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Array BioPharma stock cost?

One share of Array BioPharma stock can currently be purchased for approximately $10.36.

Array BioPharma (NASDAQ:ARRY) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Earnings History Chart

Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)

Dividend History Chart

Dividend Payments by Quarter for Array BioPharma (NASDAQ:ARRY)

Last Updated on 2/24/2017 by MarketBeat.com Staff